Shadi Halabi, MD
Interventional Cardiology · Munster, INNPI 1306285051
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (29.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Philips North America LLC at 43.0% of the total. Reporting peaked in 2023 at $8,166 and has fallen 88.1% since, to $970 in 2025.
Across 270 payments — averaging $114.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$13K
- Abbott$6K
- Boston Scientific$4K
- Cook Incorporated$1K
- Inari Medical, Inc.$806
- Medtronic$806
- plus $5K from 35 others
Across 1 payment — averaging $11,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$12K
What the payments were for
- Consulting fees$8,42327%
- Speaking & faculty fees$5,63518%
- Travel & lodging$7,53024%
- Food & beverage$8,98929%
- Education$2071%
- Entertainment$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (6554) Periph Vasc Undiv$5,635
- (6554) Peripheral Vascular Undivided$3,920
- (9520) IGT Devices Undivided$3,195
- Omnilink Elite vascular stent system$3,168
- CROSSBOSS$2,196
- SUPERA$1,233
- Zilver PTX$1,057
- FLOWTRIEVER CATHETER, S$753
- CT THROMBECTOMY SYSTEM KIT$753
- Xience V coronary stent system$560
- ANGIOJET$376
- Cook Medical Peripheral Intervention$337
- Product in Development$290
- PANTHERIS$284
- HawkOne$274
- Navicross$271
- Glidesheath$271
- GlideWire$271
- VASCULAR$263
- Indigo System$251
How this compares
$30,860 in reported general payments places this provider in the 85th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $70,131 |
| EntrestoSacubitril/Valsartan | 32 | $42,388 |
| XareltoRivaroxaban | 30 | $37,811 |
| FarxigaDapagliflozin Propanediol | 12 | $17,992 |
| BrilintaTicagrelor | 25 | $15,760 |
| Atorvastatin Calcium | 168 | $1,320 |
| Metoprolol Succinate | 80 | $1,017 |
| ClopidogrelClopidogrel Bisulfate | 69 | $538 |
| Cilostazol | 15 | $442 |
| Furosemide | 86 | $345 |
| Amlodipine Besylate | 91 | $323 |
| Carvedilol | 50 | $321 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 26 | $302 |
| Lisinopril | 27 | $167 |
| Losartan Potassium | 29 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $70,13167 claims |
| NovartisEntresto | $291 | $42,38832 claims |
| Johnson & JohnsonXarelto | $430 | $37,81130 claims |
| AstraZenecaFarxiga, Brilinta | $93 | $33,75237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Munster
- Shashidhar DivakaruniMunster$97K
- Jonathan MeyerMunster$22K
- Vinod NamanaMunster$20K
- Tariq HameedMunster$12K
- Asad TorabiMunster$11K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.